From January 1, 2024 to March 31, 2024, the company has repurchased 1,193,300 shares, representing 1.16% for CNY 42.79 million. With this, the company has completed the repurchase of 1,901,841 shares, representing 1.84% for CNY 73.56 million under the buyback announced on October 21, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.16 CNY | -5.02% |
|
-11.18% | -20.99% |
05-14 | Enwei Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023 | CI |
04-21 | Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-20.99% | 298M | |
+55.19% | 815B | |
+47.26% | 654B | |
-6.09% | 354B | |
+21.92% | 337B | |
+18.40% | 247B | |
+3.64% | 229B | |
+12.98% | 219B | |
+10.86% | 171B | |
-2.78% | 159B |
- Stock Market
- Equities
- 301331 Stock
- News Enwei Pharmaceutical Co., Ltd.
- Tranche Update on Enwei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 21, 2023.